Loading
A phase 3 trial testing TBI-1301 in sarcomas, now recruiting.
Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma is a phase 3 interventional study registered as NCT07174427, led by Takara Bio, and recruiting on the registry. Official title: Multi-centre Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma. Planned enrolment is 5 participants (estimated). The study started in 2026-01-05 and primary completion is expected in 2032-03. No results have been posted on ClinicalTrials.gov.
Shares CTAG1B, Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Synovial sarcoma, Sarcomas (soft tissue, bone, GIST).